PE20080663A1 - Terapia tumoral con una combinacion de anticuerpos anti-her2 - Google Patents
Terapia tumoral con una combinacion de anticuerpos anti-her2Info
- Publication number
- PE20080663A1 PE20080663A1 PE2007001235A PE2007001235A PE20080663A1 PE 20080663 A1 PE20080663 A1 PE 20080663A1 PE 2007001235 A PE2007001235 A PE 2007001235A PE 2007001235 A PE2007001235 A PE 2007001235A PE 20080663 A1 PE20080663 A1 PE 20080663A1
- Authority
- PE
- Peru
- Prior art keywords
- combination
- tumor therapy
- her2 antibodies
- her2
- pertuzumab
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 2
- 210000004072 lung Anatomy 0.000 abstract 2
- 229960002087 pertuzumab Drugs 0.000 abstract 2
- 238000009097 single-agent therapy Methods 0.000 abstract 2
- 229960000575 trastuzumab Drugs 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940116977 epidermal growth factor Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) TRASTUZUMAB QUE SE ADMINISTRA EN UNA DOSIS INICIAL DE 0,05MG/KG A 10MG/KG; Y B) PERTUZUMAB QUE SE ADMINISTRA EN UNA DOSIS INICIAL DE 0,05MG/KG A 10MG/KG. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE UN TIPO DE CANCER QUE SE CARACTERIZA POR UNA SOBREEXPRESION DEL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDERMAL DENOMINADO NEU (HER2) O ES HER2 POSITIVO TAL COMO CANCER DE MAMA, METASTASIS DE PULMON, ENTRE OTROS, LOS CUALES NO RESPONDEN A UNA MONOTERAPIA CON TRASTUZUMAB NI A UNA MONOTERAPIA CON PERTUZUMAB
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06019317 | 2006-09-15 | ||
| EP07006616 | 2007-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080663A1 true PE20080663A1 (es) | 2008-05-17 |
Family
ID=38608749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001235A PE20080663A1 (es) | 2006-09-15 | 2007-09-13 | Terapia tumoral con una combinacion de anticuerpos anti-her2 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080102069A1 (es) |
| AR (1) | AR062840A1 (es) |
| CL (1) | CL2007002667A1 (es) |
| PE (1) | PE20080663A1 (es) |
| TW (1) | TW200820987A (es) |
| WO (1) | WO2008031531A1 (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1447696A (zh) | 2000-05-19 | 2003-10-08 | 杰南技术公司 | 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
| DK1771482T3 (da) * | 2004-07-22 | 2014-10-20 | Genentech Inc | HER2-antistofsammensætning |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| TWI441646B (zh) | 2005-01-21 | 2014-06-21 | Genentech Inc | 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途 |
| MY152164A (en) | 2005-02-23 | 2014-08-15 | Genentech Inc | Extending time to disease progression or survival in cancer patients |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US8012914B2 (en) | 2006-10-27 | 2011-09-06 | Halliburton Energy Services, Inc. | Ortho ester breakers for viscoelastic surfactant gels and associated methods |
| SI2132573T1 (sl) | 2007-03-02 | 2014-07-31 | Genentech, Inc. | Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3 |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| US20100056555A1 (en) * | 2008-08-29 | 2010-03-04 | Enzon Pharmaceuticals, Inc. | Method of treating ras associated cancer |
| EP2337800B1 (en) | 2008-09-15 | 2013-10-02 | Yeda Research and Development Co. Ltd. | Antibody combinations and use of same for treating cancer |
| CA2738807A1 (en) * | 2008-10-21 | 2010-04-29 | Enzon Pharmaceuticals, Inc. | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| US8637084B2 (en) * | 2009-07-14 | 2014-01-28 | Asahi Kasei Medical Co., Ltd. | Treatment method for epithelial cancerous organism |
| KR20120104158A (ko) * | 2009-07-22 | 2012-09-20 | 엔즌 파마슈티칼스, 인코포레이티드 | 7-에틸-10-히드록시캠토테신의 다분지형 중합 컨쥬게이트와 ｈｅｒ２ 수용체 길항제를 병용하여 ｈｅｒ２ 양성 암을 치료하는 방법 |
| US8609095B2 (en) * | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
| JP6320753B2 (ja) | 2010-05-27 | 2018-05-09 | ゲンマブ エー／エス | Ｈｅｒ２に対するモノクローナル抗体 |
| JP6082344B2 (ja) | 2010-05-27 | 2017-02-15 | ゲンマブ エー／エス | Ｈｅｒ２エピトープに対するモノクローナル抗体 |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| JP6033783B2 (ja) * | 2010-11-01 | 2016-11-30 | シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ | Ｐａｎ−ｈｅｒ抗体組成物 |
| EP2699260B1 (en) * | 2011-04-20 | 2024-11-20 | Genmab A/S | Bispecifc antibodies against her2 |
| JP6177231B2 (ja) * | 2011-04-20 | 2017-08-09 | ゲンマブ エー／エス | Ｈｅｒ２に対する二重特異性抗体 |
| AU2012245116A1 (en) * | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
| WO2012156975A1 (en) | 2011-05-16 | 2012-11-22 | Yeda Research And Development Co. Ltd. | COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER |
| FR2976294B1 (fr) * | 2011-06-10 | 2018-02-16 | Universite De Nice Sophia Antipolis | Methode de prediction de la reponse a un traitement avec un agent bloquant her2 |
| KR102679155B1 (ko) * | 2011-10-14 | 2024-06-28 | 제넨테크, 인크. | Her2 이량체화 억제제인 페르투주맙의 용도 및 이를 포함하는 제조품 |
| EP2793941A1 (en) | 2011-12-23 | 2014-10-29 | F.Hoffmann-La Roche Ag | Articles of manufacture and methods for co-administration of antibodies |
| BR112014027291A2 (pt) | 2012-05-02 | 2017-08-08 | Symphogen As | composições de anticorpos pan-her humanizados |
| RU2737727C2 (ru) | 2013-04-16 | 2020-12-02 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
| KR101453462B1 (ko) | 2013-05-16 | 2014-10-23 | 앱클론(주) | Her2에 특이적으로 결합하는 항체 |
| MX384635B (es) * | 2014-04-16 | 2025-03-14 | Biosimilars Newco Ltd | Formulaciones de proteína estables que comprenden un exceso molar de sorbitol. |
| WO2015164665A1 (en) | 2014-04-25 | 2015-10-29 | Genentech, Inc. | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
| WO2016077739A1 (en) * | 2014-11-13 | 2016-05-19 | The Curators Of The University Of Missouri | Multiple human antibody-nanoparticle conjugates and methods of formation |
| EP3223848B1 (en) * | 2014-11-27 | 2024-11-27 | Zymeworks BC Inc. | Methods of using bispecific antigen-binding constructs targeting her2 |
| HRP20241134T1 (hr) | 2015-05-30 | 2024-11-22 | F. Hoffmann-La Roche Ag | Metode liječenja her2-pozitivnog prethodno neliječenog metastatskog raka dojke |
| TWI870335B (zh) * | 2015-06-12 | 2025-01-21 | 美商宏觀基因股份有限公司 | 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用 |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| KR101796277B1 (ko) | 2016-04-12 | 2017-11-13 | 앱클론(주) | 안정성이 개선된 ｈｅｒ２에 특이적으로 결합하는 항체 |
| MX2019005144A (es) | 2016-11-04 | 2019-10-14 | Genentech Inc | Tratamiento de cáncer de mama positivo para her2. |
| TW201827077A (zh) * | 2016-12-28 | 2018-08-01 | 美商建南德克公司 | 晚期her2表現癌症之治療 |
| KR20200113292A (ko) | 2017-01-17 | 2020-10-06 | 제넨테크, 인크. | 피하 her2 항체 제형 |
| SI3589661T1 (sl) | 2017-03-02 | 2024-03-29 | Genentech, Inc. | Adjuvansno zdravljenje her2 pozitivnega raka dojke |
| WO2018200505A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| PH12021553053A1 (en) * | 2019-06-11 | 2023-09-11 | Univ Texas | Use of an rxr agonist in treating her2+ cancers |
| JP2023532122A (ja) | 2020-06-29 | 2023-07-26 | ジェネンテック， インコーポレイテッド | ペルツズマブにトラスツズマブを加えた固定用量配合剤 |
| BR112023000707A2 (pt) * | 2020-07-14 | 2023-01-31 | Hoffmann La Roche | Ensaio de ligação para uma combinação de dose fixa, proteína, kits, composições e métodos para avaliar uma composição de dose fixa, fazer uma composição e para analisar o teor de proteína de uma combinação de dose fixa |
| KR20240119103A (ko) | 2021-12-07 | 2024-08-06 | 아이오 테라퓨틱스, 인크. | Her2+ 암 치료에서의 rxr 작용제 및 탁산의 용도 |
| AU2022407454A1 (en) | 2021-12-07 | 2024-06-06 | Board Of Regents, The University Of Texas System | Use of an rxr agonist in treating drug resistant her2+ cancers |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ516830A (en) * | 1999-06-25 | 2004-07-30 | Genentech Inc | Humanized anti-ErbB2 antibodies conjugated with a cytotoxic or chemotherapeutic agent for treating cancer |
-
2007
- 2007-09-07 WO PCT/EP2007/007802 patent/WO2008031531A1/en not_active Ceased
- 2007-09-12 TW TW096134095A patent/TW200820987A/zh unknown
- 2007-09-13 CL CL2007002667A patent/CL2007002667A1/es unknown
- 2007-09-13 PE PE2007001235A patent/PE20080663A1/es not_active Application Discontinuation
- 2007-09-13 US US11/854,584 patent/US20080102069A1/en not_active Abandoned
- 2007-09-13 AR ARP070104063A patent/AR062840A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR062840A1 (es) | 2008-12-10 |
| TW200820987A (en) | 2008-05-16 |
| CL2007002667A1 (es) | 2008-01-25 |
| US20080102069A1 (en) | 2008-05-01 |
| WO2008031531A1 (en) | 2008-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080663A1 (es) | Terapia tumoral con una combinacion de anticuerpos anti-her2 | |
| ECSP088753A (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
| DOP2012000291A (es) | 4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer de mama | |
| AR054254A1 (es) | Terapia adyuvante con trastuzumab (herceptin registrado) | |
| CO6150193A2 (es) | Terapia tumoral con anticuerpo anti-vegf | |
| AR076344A1 (es) | Metodo de terapia complementaria contra el cancer | |
| BR112019011450A2 (pt) | células naturais killer modificadas e uso das mesmas | |
| MX384605B (es) | Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno. | |
| MY186977A (en) | Tetrasubstituted alkene compounds and their use | |
| MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
| PE20090681A1 (es) | Prediccion de respuesta a un inhibidor her | |
| MX344355B (es) | Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal. | |
| PH12020550598A1 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
| GEP201706678B (en) | Method of treating cancer and bone cancer | |
| PH12012501898A1 (en) | Improved cancer therapy based on tumor associated antigens derived from cyclin d1 | |
| NI200900184A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer. | |
| SG10201810928SA (en) | Novel antitumoral use of cabazitaxel | |
| AR077972A1 (es) | Anticuerpos contra cdcp1 destinados al tratamiento del cancer | |
| MX2009009816A (es) | Anticuerpos monoclonales para el tratamiento del cancer. | |
| AR086422A1 (es) | Metodo para el tratamiento de tumores solidos avanzados, volasertib | |
| AR096184A1 (es) | Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpos para cd22-fármaco | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| NZ625758A (en) | Method for treating breast cancer | |
| SG194735A1 (en) | Compositions and methods for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |